Monitor ASCO presentations (May 30–June 1) for specific response rate, PFS, and OS data from the pumitamig and gotistobart abstracts, the interim data described is encouraging but lacks quantitative endpoints. The Phase 3 part of ROSETTA Lung-02 (pumitamig vs pembrolizumab) is the key catalyst to watch.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $92.14entry
- T+1 · 6mo ago +0.12%α −0.47% · $92.25
- T+5 · 6mo ago −0.48%α −2.15% · $91.70
- T+20 · 5mo ago −1.03%α +0.39% · $91.19
- T+60 · 3mo ago +0.66%α −2.53% · $92.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, including new clinical data for pumitamig (Phase 2 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer), plus four trial-in-progress posters across its ADC and immunotherapy pipeline. The filing is a routine pipeline update with no new financial data, guidance, or regulatory milestones, the clinical data disclosed is interim and descriptive, not definitive.
Key Facts
- BioNTech will present at ASCO 2026 (May 29–June 2) with two oral presentations and four poster presentations
- Pumitamig (PD-L1/VEGF-A bispecific) Phase 2 data in 1L NSCLC shows 'encouraging anti-tumor activity', third global dataset with consistent signal
- Gotistobart (CTLA-4) Phase 2 data in platinum-resistant ovarian cancer shows 'durable anti-tumor activity and clinically meaningful overall survival'
- Company has 25+ Phase 2/3 trials including 13 ongoing pivotal trials and novel-novel combination trials including ADCs
- No financial figures, guidance, or regulatory submission timelines were disclosed in the filing
Financial Impact
No financial data provided; pipeline update only
Risk Factors
- Interim Phase 2 data may not replicate in larger Phase 3 trials
- No regulatory filing or approval timeline provided, pipeline remains early-stage for these assets
- Competitive landscape in 1L NSCLC (pembrolizumab standard of care) and platinum-resistant ovarian cancer (limited approved options) creates high bar for differentiation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000037 |
| Document: form6-kascocurtainraiser22.htm | 0001776985-26-000037 |
| Document: 0001776985-26-000037-index-headers.html | 0001776985-26-000037 |
| Document: 0001776985-26-000037-index.html | 0001776985-26-000037 |
| Document: 0001776985-26-000037.txt | 0001776985-26-000037 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers